董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeremy Curnock Cook | 男 | Non-Executive Director | 75 | 19.55万美元 | 5.87 | 2026-02-12 |
| Jan Stern Reed | 女 | Lead Independent Director | 66 | 20.77万美元 | 7.48 | 2026-02-12 |
| Suzanne Crowe | 女 | Non-Executive Director | 75 | 19.55万美元 | 6.58 | 2026-02-12 |
| Michael Tarnoff | 男 | Non-Executive Director | 57 | 3.29万美元 | 未持股 | 2026-02-12 |
| Cary Vance | 男 | Executive Chairman of the Board and Interim Chief Executive Officer | 60 | 47.25万美元 | 4.96 | 2026-02-12 |
| Robert E. Mcnamara | -- | Non-Executive Director | 69 | 20.55万美元 | 10.06 | 2026-02-12 |
| Joe Woody | 男 | Non-Executive Director | 60 | 未披露 | 未持股 | 2026-02-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nicole Kelsey | 女 | Chief Legal and Compliance Officer and Corporate Secretary | 60 | 95.74万美元 | 7.17 | 2026-02-12 |
| Cary Vance | 男 | Executive Chairman of the Board and Interim Chief Executive Officer | 60 | 47.25万美元 | 4.96 | 2026-02-12 |
| Nicole Kelsey | -- | Chief Legal and Compliance Officer and Corporate Secretary | 59 | 未披露 | 未持股 | 2026-02-12 |
| David O'Toole | -- | Chief Financial Officer | 67 | 未披露 | 未持股 | 2026-02-12 |
| David O'Toole | 男 | Chief Financial Officer | 67 | 153.23万美元 | 26.98 | 2026-02-12 |
董事简历
中英对照 | 中文 | 英文- Jeremy Curnock Cook
-
Jeremy Curnock Cook自1995年7月以来担任董事会成员，自1998年2月以来担任董事长。从2014年9月到2015年5月他担任公司的临时首席执行官。他将辞去临时首席执行官的职务，于2015年5月18日生效，但将继续担任董事长。他自2000年以来担任International Bioscience Managers Limited（企业和投资咨询公司）的主席，担任Bioscience Managers Pty Ltd（医学科学基金经营商）的董事总经理。他从1987年到2000年担任Rothschild Asset Management Limited（企业和投资咨询公司）的董事，负责Rothschild生物科学单元。他于1975年创立the International Biochemicals Group（国际生化药剂集团），在1985年出售给Royal Dutch Shell，在那里他担任执行董事直到1987年。他持有都柏林Trinity College的自然科学硕士学位。他还担任Avita Medical Ltd, Nexus6 Ltd和SeaDragon Ltd的董事会成员。
Jeremy Curnock Cook has served as a Non-Executive Director since October 2012. He is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years.Over his career, Mr. Curnock Cook has successfully managed in excess of US $1billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and significant investor in the sector. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. He co-created a European-focused seed fund with Johnson & Johnson and built the International Biotechnology Trust. He has served on more than 40 boards of directors in the life science sector in the UK, Europe, USA, Canada, Japan and Australia. In addition to serving on Avita Medical, Inc. Board of Directors, Jeremy currently serves on the following boards: International BioScience Managers Ltd appointed March 2000, Bioscience Managers Pty Ltd appointed January 2003, REX Bionics Pty Ltd appointed February 2012, Sea Dragon appointed October 2012, Smart Matrix Ltd appointed February 2013, Adherium Ltd appointed April 2015, Bioscience Managers UK Ltd appointed August 2017, CriL appointed November 2020, and Humanetix Ltd appointed September 2021. - Jeremy Curnock Cook自1995年7月以来担任董事会成员，自1998年2月以来担任董事长。从2014年9月到2015年5月他担任公司的临时首席执行官。他将辞去临时首席执行官的职务，于2015年5月18日生效，但将继续担任董事长。他自2000年以来担任International Bioscience Managers Limited（企业和投资咨询公司）的主席，担任Bioscience Managers Pty Ltd（医学科学基金经营商）的董事总经理。他从1987年到2000年担任Rothschild Asset Management Limited（企业和投资咨询公司）的董事，负责Rothschild生物科学单元。他于1975年创立the International Biochemicals Group（国际生化药剂集团），在1985年出售给Royal Dutch Shell，在那里他担任执行董事直到1987年。他持有都柏林Trinity College的自然科学硕士学位。他还担任Avita Medical Ltd, Nexus6 Ltd和SeaDragon Ltd的董事会成员。
- Jeremy Curnock Cook has served as a Non-Executive Director since October 2012. He is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years.Over his career, Mr. Curnock Cook has successfully managed in excess of US $1billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and significant investor in the sector. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. He co-created a European-focused seed fund with Johnson & Johnson and built the International Biotechnology Trust. He has served on more than 40 boards of directors in the life science sector in the UK, Europe, USA, Canada, Japan and Australia. In addition to serving on Avita Medical, Inc. Board of Directors, Jeremy currently serves on the following boards: International BioScience Managers Ltd appointed March 2000, Bioscience Managers Pty Ltd appointed January 2003, REX Bionics Pty Ltd appointed February 2012, Sea Dragon appointed October 2012, Smart Matrix Ltd appointed February 2013, Adherium Ltd appointed April 2015, Bioscience Managers UK Ltd appointed August 2017, CriL appointed November 2020, and Humanetix Ltd appointed September 2021.
- Jan Stern Reed
-
Jan Reed最近担任沃尔格林联合博姿公司的高级副总裁，总法律顾问兼公司秘书，该公司是一家全球制药主导的健康和福利企业，年收入超过1150亿美元。在此之前，里德女士曾担任Solo Cup公司的人力资源执行Vice President、总法律顾问兼公司秘书，以及百特国际有限公司的副总法律顾问、公司秘书兼首席治理官。Reed女士在密歇根大学（University of Michigan）以优异成绩获得心理学文学学士学位，并在西北大学法学院（Northwestern University School of Law）获得法学博士学位。里德女士目前还担任Stepan Company公司（纽约证券交易所代码:SCL）的董事会成员。
Jan Stern Reed From 2013 to 2016, Ms. Reed served as Senior Vice President, General Counsel and Corporate Secretary (since 2015) at Walgreens Boots Alliance, Inc., a global pharmacy led, health and llbeing enterprise with annual revenues during her tenure in excess of $115 billion. Prior to this role, Ms. Reed served for seven years as Executive Vice President of Human Resces, General Counsel and Corporate Secretary at Solo Cup Company, and, prior thereto, as Associate General Counsel, Corporate Secretary and Chief Governance Officer at Baxter International Inc. Ms. Reed earned a Bachelor of Arts degree, with honors, in Psychology from the University of Michigan, and a Juris Doctor from Northstern University School of Law. Ms. Reed also currently serves as a member of the Board of Directors for Stepan Company (NYSE:SCL) and AVITA Medical, Inc. (Nasdaq:RCEL; ASX; AVH). Ms. Reed is a member of Audit Committee and is the Chair of the Nominating, Compliance and Corporate Governance Committee. - Jan Reed最近担任沃尔格林联合博姿公司的高级副总裁，总法律顾问兼公司秘书，该公司是一家全球制药主导的健康和福利企业，年收入超过1150亿美元。在此之前，里德女士曾担任Solo Cup公司的人力资源执行Vice President、总法律顾问兼公司秘书，以及百特国际有限公司的副总法律顾问、公司秘书兼首席治理官。Reed女士在密歇根大学（University of Michigan）以优异成绩获得心理学文学学士学位，并在西北大学法学院（Northwestern University School of Law）获得法学博士学位。里德女士目前还担任Stepan Company公司（纽约证券交易所代码:SCL）的董事会成员。
- Jan Stern Reed From 2013 to 2016, Ms. Reed served as Senior Vice President, General Counsel and Corporate Secretary (since 2015) at Walgreens Boots Alliance, Inc., a global pharmacy led, health and llbeing enterprise with annual revenues during her tenure in excess of $115 billion. Prior to this role, Ms. Reed served for seven years as Executive Vice President of Human Resces, General Counsel and Corporate Secretary at Solo Cup Company, and, prior thereto, as Associate General Counsel, Corporate Secretary and Chief Governance Officer at Baxter International Inc. Ms. Reed earned a Bachelor of Arts degree, with honors, in Psychology from the University of Michigan, and a Juris Doctor from Northstern University School of Law. Ms. Reed also currently serves as a member of the Board of Directors for Stepan Company (NYSE:SCL) and AVITA Medical, Inc. (Nasdaq:RCEL; ASX; AVH). Ms. Reed is a member of Audit Committee and is the Chair of the Nominating, Compliance and Corporate Governance Committee.
- Suzanne Crowe
-
Suzanne Crowe自2016年1月起担任非执行董事。Australian-based，她是一名医生科学家和公司董事，在支持公司的医疗和科学战略方面拥有丰富的专业知识。克罗教授是澳大利亚国家卫生和医学研究委员会的主要研究员。她是墨尔本阿尔弗雷德医院（the Alfred Hospital，Melbourne）传染病首席专家和墨尔本莫纳什大学（Monash University，Melbourne）医学和传染病兼职教授，并发表了200多篇同行评议论文。Crowe教授是澳大利亚公司董事协会的成员，也是澳大利亚最大的非营利性健康和老年护理提供商St Vincents Health Australia的董事。Crowe教授于2011年被任命为Australia AM勋章成员，以表彰她对艾滋病毒/艾滋病医学研究的服务。她拥有Monash University的医学和医学博士学位，the Royal Australasian College of Physicians的传染病内科专家资格，以及the Royal Melbourne Institute of Technology的医学实验室技术文凭。
Suzanne Crowe has served as a Director since January 2016. Atralian based, she is a physician scientist, and as a director, has expertise in supporting companies with their medical and scientific strategies. Professor Cro is an Emerit Professor at Monash University Melbne, and she recently retired after 35 years of service as both Associate Director Clinical Research at the Burnet Institute and Senior Specialist Physician in Infectio Diseases at The Alfred Hospital Melbne. A Fellow of the Atralian Institute of Company Directors, she is currently a Director of Sonic Healthcare Ltd, a large global medical diagnostics company. In addition, Professor Cro served on the board of St. Vincent's Health Atralia Ltd., the country's largest not for profit health and aged care provider, from 2012 to2021. In June 2020, she was appointed as Officer of the Order of Atralia in recognition of her distinguished services to health, clinical governance, biomedical research, and education. - Suzanne Crowe自2016年1月起担任非执行董事。Australian-based，她是一名医生科学家和公司董事，在支持公司的医疗和科学战略方面拥有丰富的专业知识。克罗教授是澳大利亚国家卫生和医学研究委员会的主要研究员。她是墨尔本阿尔弗雷德医院（the Alfred Hospital，Melbourne）传染病首席专家和墨尔本莫纳什大学（Monash University，Melbourne）医学和传染病兼职教授，并发表了200多篇同行评议论文。Crowe教授是澳大利亚公司董事协会的成员，也是澳大利亚最大的非营利性健康和老年护理提供商St Vincents Health Australia的董事。Crowe教授于2011年被任命为Australia AM勋章成员，以表彰她对艾滋病毒/艾滋病医学研究的服务。她拥有Monash University的医学和医学博士学位，the Royal Australasian College of Physicians的传染病内科专家资格，以及the Royal Melbourne Institute of Technology的医学实验室技术文凭。
- Suzanne Crowe has served as a Director since January 2016. Atralian based, she is a physician scientist, and as a director, has expertise in supporting companies with their medical and scientific strategies. Professor Cro is an Emerit Professor at Monash University Melbne, and she recently retired after 35 years of service as both Associate Director Clinical Research at the Burnet Institute and Senior Specialist Physician in Infectio Diseases at The Alfred Hospital Melbne. A Fellow of the Atralian Institute of Company Directors, she is currently a Director of Sonic Healthcare Ltd, a large global medical diagnostics company. In addition, Professor Cro served on the board of St. Vincent's Health Atralia Ltd., the country's largest not for profit health and aged care provider, from 2012 to2021. In June 2020, she was appointed as Officer of the Order of Atralia in recognition of her distinguished services to health, clinical governance, biomedical research, and education.
- Michael Tarnoff
-
迈克尔·塔诺夫（Michael Tarnoff），最近担任首席医师执行官兼首席执行官，任期至2024年。在塔夫茨大学担任多个领导职务期间，塔尔诺夫博士于2015年至2019年在美敦力公司担任首席医疗官兼医疗事务副总裁。在任职于美敦力之前，从2008年到2015年，Tarnoff博士在Covidien PLC担任公司首席医疗官兼医疗事务副总裁，在此之前，担任手术器械部门的首席医疗官兼医疗事务副总裁。其他行政领导经验包括2006年至2008年在GI Dynamics，Inc.担任医疗总监，以及2005年至2008年在Tyco Healthcare的Kendall手术部门担任首席医疗顾问。在获得圣路易斯华盛顿大学的文学学士学位后，塔尔诺夫博士获得了新泽西州医学和牙科大学的医学学位。随后，他在罗格斯医学院完成了普通外科住院医师，随后在克利夫兰诊所获得了腹腔镜手术高级研究金。
Michael Tarnoff,most recently as the Chief Physician Executive and CEO, until 2024. While serving in various leadership positions at Tufts, Dr. Tarnoff served as Chief Medical Officer and Vice President, Medical Affairs at Medtronic, Inc. from 2015 to 2019. Before working for Medtronic, from 2008 through 2015, Dr. Tarnoff was the Corporate Chief Medical Officer and Vice President, Medical Affairs, and before that position, the Chief Medical Officer and Vice President, Medical Affairs of the Surgical Devices division, at Covidien plc. Additional executive leadership experience includes roles serving as Medical Director at GI Dynamics, Inc. from 2006 to 2008, as well as Chief Medical Consultant to the Kendall surgery unit of Tyco Healthcare from 2005 to 2008. After earning a Bachelor of Arts degree from Washington University in St. Louis, Dr. Tarnoff received his medical degree from the University of Medicine and Dentistry of New Jersey. He then completed a general surgery residency at Rutgers Medical School, followed by an advanced fellowship in laparoscopic surgery at the Cleveland Clinic. - 迈克尔·塔诺夫（Michael Tarnoff），最近担任首席医师执行官兼首席执行官，任期至2024年。在塔夫茨大学担任多个领导职务期间，塔尔诺夫博士于2015年至2019年在美敦力公司担任首席医疗官兼医疗事务副总裁。在任职于美敦力之前，从2008年到2015年，Tarnoff博士在Covidien PLC担任公司首席医疗官兼医疗事务副总裁，在此之前，担任手术器械部门的首席医疗官兼医疗事务副总裁。其他行政领导经验包括2006年至2008年在GI Dynamics，Inc.担任医疗总监，以及2005年至2008年在Tyco Healthcare的Kendall手术部门担任首席医疗顾问。在获得圣路易斯华盛顿大学的文学学士学位后，塔尔诺夫博士获得了新泽西州医学和牙科大学的医学学位。随后，他在罗格斯医学院完成了普通外科住院医师，随后在克利夫兰诊所获得了腹腔镜手术高级研究金。
- Michael Tarnoff,most recently as the Chief Physician Executive and CEO, until 2024. While serving in various leadership positions at Tufts, Dr. Tarnoff served as Chief Medical Officer and Vice President, Medical Affairs at Medtronic, Inc. from 2015 to 2019. Before working for Medtronic, from 2008 through 2015, Dr. Tarnoff was the Corporate Chief Medical Officer and Vice President, Medical Affairs, and before that position, the Chief Medical Officer and Vice President, Medical Affairs of the Surgical Devices division, at Covidien plc. Additional executive leadership experience includes roles serving as Medical Director at GI Dynamics, Inc. from 2006 to 2008, as well as Chief Medical Consultant to the Kendall surgery unit of Tyco Healthcare from 2005 to 2008. After earning a Bachelor of Arts degree from Washington University in St. Louis, Dr. Tarnoff received his medical degree from the University of Medicine and Dentistry of New Jersey. He then completed a general surgery residency at Rutgers Medical School, followed by an advanced fellowship in laparoscopic surgery at the Cleveland Clinic.
- Cary Vance
-
卡里万斯于2025年10月被任命为公司临时首席执行官，自2025年8月起担任董事会主席，自2023年4月起担任董事。万斯先生在医疗保健行业拥有超过25年的丰富领导经验，具有商业和运营专长。他于2023年5月至2025年1月担任PhotoniCare，Inc.总裁兼首席执行官。在此任命之前，他是Titan Medical的总裁兼首席执行官，并担任其董事会独立董事至2024年11月。此前，万斯先生曾担任XCAH的总裁兼首席执行官，XCAH是一家私营的神经血管机器人公司，也曾在OptiScan Biomedical、Myoscience和汉森医疗担任过类似职务。他支持这些公司，因为它们凭借颠覆性、赋能和改变游戏规则的新技术实现了市场商业化和变革。在任职于汉森医疗之前，他曾在泰利福、Covidien和GE Healthcare担任多个全球执行领导职务。Vance先生获得Lean/Six Sigma Black Belt认证、NACD认证，同时拥有马凯特大学经济学文学士学位和MBA学位。
Cary Vance was appointed Interim CEO of the Company in October 2025 and has served as Chairman of the Board since August 2025 and Director since April 2023. Mr. Vance has over 25 years of extensive leadership experience in the healthcare industry with commercial and operational expertise. He served as the President and Chief Executive Officer of PhotoniCare, Inc., from May 2023 until January 2025. Prior to this appointment, he was President and CEO of Titan Medical, and he served as an independent director for its Board of Directors through November 2024. Previously, Mr. Vance served as President and CEO of XCath, a privately held neurovascular robotics company, having also served in similar roles at OptiScan Biomedical, Myoscience, and Hansen Medical. He supported these companies as they commercialized and transformed markets with their disruptive, enabling, and game-changing novel technologies. Prior to his role at Hansen Medical, he served in various global executive leadership roles at Teleflex, Covidien, and GE HealthCare. Mr. Vance is Lean/Six Sigma Black Belt Certified, NACD Certified, and holds both a Bachelor of Arts degree in Economics and an MBA from Marquette University. - 卡里万斯于2025年10月被任命为公司临时首席执行官，自2025年8月起担任董事会主席，自2023年4月起担任董事。万斯先生在医疗保健行业拥有超过25年的丰富领导经验，具有商业和运营专长。他于2023年5月至2025年1月担任PhotoniCare，Inc.总裁兼首席执行官。在此任命之前，他是Titan Medical的总裁兼首席执行官，并担任其董事会独立董事至2024年11月。此前，万斯先生曾担任XCAH的总裁兼首席执行官，XCAH是一家私营的神经血管机器人公司，也曾在OptiScan Biomedical、Myoscience和汉森医疗担任过类似职务。他支持这些公司，因为它们凭借颠覆性、赋能和改变游戏规则的新技术实现了市场商业化和变革。在任职于汉森医疗之前，他曾在泰利福、Covidien和GE Healthcare担任多个全球执行领导职务。Vance先生获得Lean/Six Sigma Black Belt认证、NACD认证，同时拥有马凯特大学经济学文学士学位和MBA学位。
- Cary Vance was appointed Interim CEO of the Company in October 2025 and has served as Chairman of the Board since August 2025 and Director since April 2023. Mr. Vance has over 25 years of extensive leadership experience in the healthcare industry with commercial and operational expertise. He served as the President and Chief Executive Officer of PhotoniCare, Inc., from May 2023 until January 2025. Prior to this appointment, he was President and CEO of Titan Medical, and he served as an independent director for its Board of Directors through November 2024. Previously, Mr. Vance served as President and CEO of XCath, a privately held neurovascular robotics company, having also served in similar roles at OptiScan Biomedical, Myoscience, and Hansen Medical. He supported these companies as they commercialized and transformed markets with their disruptive, enabling, and game-changing novel technologies. Prior to his role at Hansen Medical, he served in various global executive leadership roles at Teleflex, Covidien, and GE HealthCare. Mr. Vance is Lean/Six Sigma Black Belt Certified, NACD Certified, and holds both a Bachelor of Arts degree in Economics and an MBA from Marquette University.
- Robert E. Mcnamara
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Joe Woody
-
Joe Woody，最近于2017年至2024年担任Avanos Medical的首席执行官，此前担任Acelity Holdings总裁兼首席执行官。他的背景涵盖多个高级管理职务，包括在Covidien和施乐辉任职。伍迪先生还曾在AdvaMed，Inc.的董事会任职十多年，该公司是美国医疗设备、诊断和数字健康技术领域最大的行业协会。
Joe Woody,most recently serving as CEO of Avanos Medical from 2017 to 2024, and previously, as President and CEO of Acelity Holdings. His background spans multiple senior executive roles, including with Covidien and Smith & Nephew. Mr. Woody also served on the Board of Directors of AdvaMed, Inc., the largest trade association in the U.S. for the medical device, diagnostics, and digital health technology sectors, for over a decade. - Joe Woody，最近于2017年至2024年担任Avanos Medical的首席执行官，此前担任Acelity Holdings总裁兼首席执行官。他的背景涵盖多个高级管理职务，包括在Covidien和施乐辉任职。伍迪先生还曾在AdvaMed，Inc.的董事会任职十多年，该公司是美国医疗设备、诊断和数字健康技术领域最大的行业协会。
- Joe Woody,most recently serving as CEO of Avanos Medical from 2017 to 2024, and previously, as President and CEO of Acelity Holdings. His background spans multiple senior executive roles, including with Covidien and Smith & Nephew. Mr. Woody also served on the Board of Directors of AdvaMed, Inc., the largest trade association in the U.S. for the medical device, diagnostics, and digital health technology sectors, for over a decade.
高管简历
中英对照 | 中文 | 英文- Nicole Kelsey
Nicole Kelsey自2017年8月起担任我们的总法律顾问兼秘书。她的专业领域包括美国证券法，国际并购和公司治理。在加入Amyris之前，她在巴黎担任了全球商业营销的全球领导者Criteo的总法律顾问和秘书超过三年。在加入Criteo之前，Kelsey女士是全球医疗技术领导者美敦力公司的高级证券律师。她曾担任CIT Group，Inc.的首席并购律师。是一家私人商人银行的总顾问；并为国际企业集团维旺迪（Vivendi）工作。在进入公司内部之前，凯尔西女士曾在巴黎和纽约的White＆Case和Willkie，Farr＆Gallagher律师事务所执业。 Kelsey女士是富布赖特大学的学者，拥有西北大学的法学博士学位和学士学位。来自俄亥俄州立大学。
Nicole Kelsey has served as our General Counsel and Secretary since August 2017. Ms. Kelsey has over 25 years of experience as an executive leader for public companies with international operations. Her areas of expertise has served as our General Counsel and Secretary since August 2017. Ms. Kelsey has over 25 years of experience as an executive leader for public companies with international operations. Her areas of expertise.- Nicole Kelsey自2017年8月起担任我们的总法律顾问兼秘书。她的专业领域包括美国证券法，国际并购和公司治理。在加入Amyris之前，她在巴黎担任了全球商业营销的全球领导者Criteo的总法律顾问和秘书超过三年。在加入Criteo之前，Kelsey女士是全球医疗技术领导者美敦力公司的高级证券律师。她曾担任CIT Group，Inc.的首席并购律师。是一家私人商人银行的总顾问；并为国际企业集团维旺迪（Vivendi）工作。在进入公司内部之前，凯尔西女士曾在巴黎和纽约的White＆Case和Willkie，Farr＆Gallagher律师事务所执业。 Kelsey女士是富布赖特大学的学者，拥有西北大学的法学博士学位和学士学位。来自俄亥俄州立大学。
- Nicole Kelsey has served as our General Counsel and Secretary since August 2017. Ms. Kelsey has over 25 years of experience as an executive leader for public companies with international operations. Her areas of expertise has served as our General Counsel and Secretary since August 2017. Ms. Kelsey has over 25 years of experience as an executive leader for public companies with international operations. Her areas of expertise.
- Cary Vance
卡里万斯于2025年10月被任命为公司临时首席执行官，自2025年8月起担任董事会主席，自2023年4月起担任董事。万斯先生在医疗保健行业拥有超过25年的丰富领导经验，具有商业和运营专长。他于2023年5月至2025年1月担任PhotoniCare，Inc.总裁兼首席执行官。在此任命之前，他是Titan Medical的总裁兼首席执行官，并担任其董事会独立董事至2024年11月。此前，万斯先生曾担任XCAH的总裁兼首席执行官，XCAH是一家私营的神经血管机器人公司，也曾在OptiScan Biomedical、Myoscience和汉森医疗担任过类似职务。他支持这些公司，因为它们凭借颠覆性、赋能和改变游戏规则的新技术实现了市场商业化和变革。在任职于汉森医疗之前，他曾在泰利福、Covidien和GE Healthcare担任多个全球执行领导职务。Vance先生获得Lean/Six Sigma Black Belt认证、NACD认证，同时拥有马凯特大学经济学文学士学位和MBA学位。
Cary Vance was appointed Interim CEO of the Company in October 2025 and has served as Chairman of the Board since August 2025 and Director since April 2023. Mr. Vance has over 25 years of extensive leadership experience in the healthcare industry with commercial and operational expertise. He served as the President and Chief Executive Officer of PhotoniCare, Inc., from May 2023 until January 2025. Prior to this appointment, he was President and CEO of Titan Medical, and he served as an independent director for its Board of Directors through November 2024. Previously, Mr. Vance served as President and CEO of XCath, a privately held neurovascular robotics company, having also served in similar roles at OptiScan Biomedical, Myoscience, and Hansen Medical. He supported these companies as they commercialized and transformed markets with their disruptive, enabling, and game-changing novel technologies. Prior to his role at Hansen Medical, he served in various global executive leadership roles at Teleflex, Covidien, and GE HealthCare. Mr. Vance is Lean/Six Sigma Black Belt Certified, NACD Certified, and holds both a Bachelor of Arts degree in Economics and an MBA from Marquette University.- 卡里万斯于2025年10月被任命为公司临时首席执行官，自2025年8月起担任董事会主席，自2023年4月起担任董事。万斯先生在医疗保健行业拥有超过25年的丰富领导经验，具有商业和运营专长。他于2023年5月至2025年1月担任PhotoniCare，Inc.总裁兼首席执行官。在此任命之前，他是Titan Medical的总裁兼首席执行官，并担任其董事会独立董事至2024年11月。此前，万斯先生曾担任XCAH的总裁兼首席执行官，XCAH是一家私营的神经血管机器人公司，也曾在OptiScan Biomedical、Myoscience和汉森医疗担任过类似职务。他支持这些公司，因为它们凭借颠覆性、赋能和改变游戏规则的新技术实现了市场商业化和变革。在任职于汉森医疗之前，他曾在泰利福、Covidien和GE Healthcare担任多个全球执行领导职务。Vance先生获得Lean/Six Sigma Black Belt认证、NACD认证，同时拥有马凯特大学经济学文学士学位和MBA学位。
- Cary Vance was appointed Interim CEO of the Company in October 2025 and has served as Chairman of the Board since August 2025 and Director since April 2023. Mr. Vance has over 25 years of extensive leadership experience in the healthcare industry with commercial and operational expertise. He served as the President and Chief Executive Officer of PhotoniCare, Inc., from May 2023 until January 2025. Prior to this appointment, he was President and CEO of Titan Medical, and he served as an independent director for its Board of Directors through November 2024. Previously, Mr. Vance served as President and CEO of XCath, a privately held neurovascular robotics company, having also served in similar roles at OptiScan Biomedical, Myoscience, and Hansen Medical. He supported these companies as they commercialized and transformed markets with their disruptive, enabling, and game-changing novel technologies. Prior to his role at Hansen Medical, he served in various global executive leadership roles at Teleflex, Covidien, and GE HealthCare. Mr. Vance is Lean/Six Sigma Black Belt Certified, NACD Certified, and holds both a Bachelor of Arts degree in Economics and an MBA from Marquette University.
- Nicole Kelsey
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- David O'Toole
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- David O'Toole
David O'Toole ，2012年4月开始就是MediciNova, Inc.董事。2012年9月开始他就是克迪科思公司（Codexis, Inc.一家生物技术公司）的高级副总裁和首席财务官。2010年5月到2012年9月，他是反应遗传学公司（Response Genetics 一家生命科学公司）的首席财务官和副总裁。2008年6月到2009年8月，他是阿博利斯科学公司（ Abraxis Bioscience, Inc. 一家生物技术公司）的执行副总裁和首席财务官。1997年到2008年，他是德勤会计师事务所（Deloitte & Touche LLP）的合伙人。他获得了亚利桑那大学（the University of Arizona）的会计学士学位。
David O'Toole has served as a director since April 2012. Since September 2012 Mr. O'Toole has served as Senior Vice President and Chief Financial Officer of Codexis, Inc., a biotechnology company. From May 2010 until September 2012 Mr. O'Toole was Vice President and Chief Financial Officer of Response Genetics, a life sciences company. From June 2008 until August 2009 Mr. O'Toole was Executive Vice President and Chief Financial Officer at Abraxis Bioscience, Inc. a biotechnology company. From 1997 until 2008 Mr. O'Toole served as a partner with Deloitte & Touche LLP. Mr. O'Toole received a B.S. in Accounting from the University of Arizona. Mr. O'Toole was appointed to the Board following a search for a suitable director to serve as the Chairman of the audit committee and who also meets the financial sophistication requirements under applicable Nasdaq rules. The company engaged Levin and Company, Inc., or Levin, to assist in this search and multiple candidates were interviewed by the Board prior to Mr. O'Toole's appointment.- David O'Toole ，2012年4月开始就是MediciNova, Inc.董事。2012年9月开始他就是克迪科思公司（Codexis, Inc.一家生物技术公司）的高级副总裁和首席财务官。2010年5月到2012年9月，他是反应遗传学公司（Response Genetics 一家生命科学公司）的首席财务官和副总裁。2008年6月到2009年8月，他是阿博利斯科学公司（ Abraxis Bioscience, Inc. 一家生物技术公司）的执行副总裁和首席财务官。1997年到2008年，他是德勤会计师事务所（Deloitte & Touche LLP）的合伙人。他获得了亚利桑那大学（the University of Arizona）的会计学士学位。
- David O'Toole has served as a director since April 2012. Since September 2012 Mr. O'Toole has served as Senior Vice President and Chief Financial Officer of Codexis, Inc., a biotechnology company. From May 2010 until September 2012 Mr. O'Toole was Vice President and Chief Financial Officer of Response Genetics, a life sciences company. From June 2008 until August 2009 Mr. O'Toole was Executive Vice President and Chief Financial Officer at Abraxis Bioscience, Inc. a biotechnology company. From 1997 until 2008 Mr. O'Toole served as a partner with Deloitte & Touche LLP. Mr. O'Toole received a B.S. in Accounting from the University of Arizona. Mr. O'Toole was appointed to the Board following a search for a suitable director to serve as the Chairman of the audit committee and who also meets the financial sophistication requirements under applicable Nasdaq rules. The company engaged Levin and Company, Inc., or Levin, to assist in this search and multiple candidates were interviewed by the Board prior to Mr. O'Toole's appointment.